Drugs / V001-BCMA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07395479 | Nov 2025 → Dec 2027 expected | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 0 | NCT07339540 | Nov 2025 → Oct 2028 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, immunoglobulin G4-related sclerosing disease, systemic lupus erythematosus +1 | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V001-BCMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07395479 ↗ |
| Action | Deplete | “These CAR-T cells can then specifically kill target cells.” NCT07339540 ↗ |
| Modality | Cell therapy | “An in vivo CAR-T drug” NCT07395479 ↗ |
| Route | Intravenous | “administered intravenously” NCT07395479 ↗ |